natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the anti-FGFR2IIIb antibodies comprise a k light chain constant region, an IgG1 heavy chain constant region, or a k light chain constant region and an IgG1 heavy chain constant region. The method of claim 1, wherein the afucosylated antibodies have enhanced ADCC activity in vitro compared to a fucosylated anti-FGFR2IIIb antibody having the same amino acid sequence. 
Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time što afukozilirana protutijela imaju poboljšanu in vitro ADCC aktivnost u usporedbi s fukoziliranim anti-FGFR2IIIb protutijelom koje ima istu sekvencu aminokiseline; i/ili pri čemu afukozilirana protutijela imaju povećani afinitet za Fc gama RIIIA u usporedbi s fukoziliranim anti-FGFR2IIIb protutijelom koje ima istu sekvencu aminokiseline.
The present invention relates to a method for producing expanded metal profiles, and a profile produced by the method, in accordance with the preamble of the independent claims (see WO 01/42583 A). 
Predmetni izum se odnosi na postupak za proizvodnju rastegnutih metalnih profila i na profile koji su proizvedeni tim postupkom, koji su u skladu s uvodnim dijelom neovisnih patentnih zahtjeva (vidi WO 01/42583 A).
Addition of methyl 4-amino-benzoate to the chloroimidate followed by amide formation with the appropriate amine gives the desired compounds. 
Dodavanje metal-4-amino-benzoata ka klorimidatu, nakon čega slijedi stvaranje amida pomoću odgovarajućeg amina daje željene spojeve.
Distributor power line communication system comprising: 
Sustav distribucije komunikacije preko elektroenergetske mreže (Power Line Communication, PLC) koji uključuje:
Inhibition of LDL transcytosis in human microvascular endothelial cells (% of inhibition to control (mean ± s.e.m.)) 
Inhibicija LDL transcitoze u humanim mikrovaskularnim endotelnim stanicama (% inhibicije prema kontroli (prosjek + s.e.m.))
The method according to claim 16, wherein the component e) is selected among anionic surfactants. 
Metoda u skladu sa patentnim zahtjevom 16, naznačena time da je komponenta označena slovom e) odabrana između anionskih aktivnih tvari.
Beverage preparation machine according to any of claims 2 to 4, characterized in that said first actuation part (71) is disposed further distanced from said chassis (2) and configured at least approximately in form of a box, and in that, other actuation parts are configured at least approximately in a ring-like form. 
Stroj za pripremanje napitaka prema bilo kojem od patentnih zahtjeva 2 do 4, naznačen time, da je navedeni prvi dio za pokretanje (71) postavljen dalje od navedenog kućišta (2) 1 oblikovan barem približno u obliku kutije, a da su drugi dijelovi za pokretanje konfigurirani barem približno u obliku prstena.
Generally, these can be antibodies (especially monoclonal antibodies) or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance. 
Konjugat u skladu s patentnim zahtjevom 12 ili 13, naznačen time što navedeno sredstvo za vezanje na stanicu se bira između protutijela, fragmenta protutijela koji sadrži najmanje jedno mjesto vezanja, limfokina, hormona, čimbenika rasta, molekula za transport nutricijenata.
A pharmaceutical composition comprising the compound N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein said composition further comprises: a pharmaceutically acceptable carrier or adjuvant; and an additional agent selected from a mucolytic agent, bronchodilator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, cystic fibrosis transmembrane receptor (CFTR) modulator, or a nutritional agent. 
PATENTNI ZAHTJEVI snom Farmaceutski pripravak koji sadrži spoj N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid ili njegovu farmaceutski prihvatljivu sol, pri čemu navedeni pripravak nadalje sadrži: a) farmaceutski prihvatljiv nosač ili adjuvant; i b) dodatno sredstvo odabrano od mukolitičkog sredstva, bronhodilatatora, antibiotika, antiinfektivnog sredstva, protuupalnog sredstva, modulatora cistično fibroznog transmembranskog receptora (CFTR) ili prehrambenog sredstva.
As shown in the exemplary blender container 106 depicted in Figure 7, a juicer 111 may be provided within the body of the blender container 106. 
Kako je prikazano na primjeru posude mješalice 106 na Slici 7, unutar tijela posude mješalice 106 može se nalaziti sokovnik 111.
at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from 4,000,000 and 7,000,000; and 
najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; te
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1, additionally comprising an inlet for introducing at least one solid medicinal pill into said chamber (104; 204; 404) to be dispensed via said outlet (106; 506). 
Spremnik (100; 200; 400; 500), namijenjen držanju 1 izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, dodatno sadrži ulaz za uvođenje najmanje jedne čvrste medicinske pilule u navedenu komoru (104; 204; 404), radi izdavanja putem navedenog izlaza (106; 506).
Preferably, according to the second aspect of the invention the connection means are arranged for coaxial alignment of the opening of the lid with the second end of the dispensing line channel. 
- < usmjeravanje otvora (19) na poklopcu (5) u skladu s otvorom drugog kraja (8) priključnog kanala za točenje (7), te
Typically, the yield of the present process is in the range of 5-90%, especially in the range of 10-80%. 
Tipično, prinos sadašnjeg postupka je u opsegu od 5-90%, naročito u opsegu od 10-80%.
shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute. 
(b) oblikovanje sastava kako bi se dobila formulacija matrice s produljenim otpuštanjem; i (c) stvrdnjavanje navedene formulacije matrice s produljenim otpuštanjem koje sadrži barem korak stvrdnjavanja u kojem se formulacija matrice s produljenim otpuštanjem podvrgava temperaturi koja je barem temperatura omekšavanja navedenog polietilen oksida u periodu od barem oko 1 minute.
A method for detecting cell proliferative disorders, according to any of claims 1, comprising: 
Postupak otkrivanja raka pluća, dojke ili mjehura prema zahtjevu 1 ili 2, obuhvaća:
a second polyol, the second polyol being selected from propylene glycol, glycerine or a combination thereof, the concentration of the second polyol being at least 0.1 w/v% but less than 5 w/v% of the composition; 
drugi poliol, te je drugi poliol odabran od propilen glikola, glicerina ili njihove kombinacije, pri čemu je koncentracija drugog poliola najmanje 0,1 m/v% ali manja od 5 m/v% pripravka;
The base station apparatus according to claim 6, wherein L is a sum of LCW#0 and LCW#1. 
Uređaj bazna stanica sukladno zahtjevu 6, naznačen time da je L zbroj Lewaol Low. DE ba i re tana
cooling an aqueous solution containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide and meglumine to produce a frozen product; 
hlađenja vodene otopine koja sadrži 6-fluoro-3-hidroksi-2-pirazinkarboxamida i meglumin kako bi se proizveo amorfni zamrznuti produkt megluminske soli 6-fluoro-3- h id rosk i-2-p i razi nkarboksam ida;
Separation can be carried out by forming a salt with a chiral acid such as (+) or (-) camphorsulphonic acid, separating the resulting diastereoisomers by fractional crystallisation to give a salt of a single enantiomer and then releasing the free base from the salt. 
Odijeljivanje se može provesti formiranjem soli s hiralnom kiselinom poput (+) ili (-) kamforsulfonske kiseline, odijeljivanjem rezultirajućih dijastereoizomera frakcijskom kristalizacijom da bi se dobila sol pojedinačnog enantiomera i zatim oslobađanjem slobodne baze iz soli.
Method according to anyone of claims 1 to 4, wherein the concentrator (C) transmits values indicating storage locations to the remote meter (RM) requesting transmission of consumption related data stored in the storage locations indicated by said values. 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu sabirnik (C) prenosi vrijednosti koje označuju lokacije za pohranu do daljinskog brojača (RM) zahtijevajući prijenos navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju pohranjenih na lokacijama za pohranu označenim navedenim vrijednostima.
30 minutes prior to behavioural testing. Results 
30 minuta prije ispitivanja ponašanja. Rezultati
Examples of liquid carriers are syrup, peanut oil, olive oil, phospho lipids, fatty acids, fatty acid amines, polyoxyethylene and water. 
Primjeri tekućih nosača su sirupi, ulje kikirikija, maslinovo ulje, fosfo-lipidi, masni kiseli amini, polioksietilen i voda.
E is a methyl linker which is substituted by aminomethyl, wherein the amino group of the aminomethyl is unsubstituted, or mono- or disubstituted by LA, or E is a methyl linker which is substituted by (azetidin-1-yl)methyl, in Subformula 6 
E je metilna poveznica koja je supstituirana s aminometilom, pri čemu je amino skupina od aminometila nesupstituirana, ili mono- ili disupstituirana s LA, ili E je metilna poveznica koji je supstituirana s (azetidin-1- il)metil, ili u Podformuli 7 XjeN,
wherein the portions add up to 100%. The binder according to claim 2, wherein relative to the total binder, 15 to 70% by weight of ternesite and 30 to 85% by weight of latently hydraulic and/or pozzolanic material is included, wherein portions of these in combination with those of remaining binder components add up to 100%. The binder according to claim 12, wherein relative to the total binder, 20 to 60% by weight of ternesite and 40 to 80% by weight of latently hydraulic and/or pozzolanic material is included, wherein portions of these in combination with those of remaining binder components add up to 100%. 
Vezivo sukladno zahtjevu 3, naznačeno time što sadrži klinker kalcijevog sulfoaluminata u količimi opsega od 10 do 90 % mase, poželjno 20 do 70 % mase i ternesit klinker u količini opsega od 10 do 90 % mase, poželjno 30 do 80 % mase, pri čemu sve komponente veziva iznose do 100 %. Vezivo sukladno zahtjevu 3 ili 4, naznačeno time što latentni hidraulički materijali i/ili puzolani su sadržani u opsegu 5 do 80 % mase, poželjno od 20 do 60 % mase.
Use according to any one of the preceding claims, characterized in that said calcium carbonate-comprising material comprises at least 50 %, preferably at least 80 %, and more preferably at least 98 %, by weight of calcium carbonate relative to the total weight of said calcium carbonate-comprising material. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da navedeni materijal koji sadrži kalcijev karbonat sadrži najmanje 50 %, poželjno najmanje 80 % i poželjnije najmanje 98 %, po težini kalcijevog karbonata u odnosu na ukupnu težinu navedenog materijala koji sadrži kalcijev karbonat.
A compound according to Formula I, wherein R1 is selected from the group consisting of -OH, ORa, and NRbRc; 
Spoj formule I, [image] naznačen time da, je odabran iz skupine koju čine -OH, ORa, i NRbRc;
The pressure in the capsule 101 increases and the tear face 104 increasingly follows the shape of the radial opening relief members 113. 
Tlak u čahuri 101 se povećava i ploha 104 koja se trga se povećava i slijedi oblik radijalnih ispusnih elemenata 113 s otvorom.
To the said dispersion 8.4 g of propylene glycol dissolved in 240 g of water were added. 
Navedenoj disperziji dodano je 8,4 g propilen glikola koji je otopljen u 240 g vode.
Scheme 2 illustrates the preparation of individual dihydrotetrabenazine isomers having the 2 R,3 S,11b R and 2 S,3 R,11b S configurations in which the hydrogen atoms attached to the 2- and 3-positions are arranged in a cis relative orientation. 
Shema 2 prikazuje pripremu pojedinačnih izomera dihidrotetrabenazina koji imaju 2R,35,1IbR 1 25,3R,11bS konfiguracije u kojima su vodikovi atomi vezani u položajima 2- 1 3- smješteni u cis relativnoj orijentaciji.
The method according to claim 2, wherein forming the amino acid supplemented milk source comprises addition of at least one component selected from the group consisting of an amino acid, a protease and a peptidase to the milk source. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što se dobivanje izvora mlijeka s dodanim aminokiselinama sastoji u najmanje jednom od dodavanja najmanje jedne aminokiseline, dodavanja proteaze ili dodavanja peptidaze izvoru mlijeka.
An aqueous composition according to claim 1, which has been stored at temperatures higher than 20°C for at least 1 month. 
Vodeni pripravak sukladno zahtjevu 1, naznačen time što je najmanje 1 mjesec pohranjen na temperaturama višim od 20*C.
C3-5cycloalkyl substituted with one group selected from: -C(O)OR9, -C(O)NR9R10, 
C3-5cikloalkil supstituiran s jednom skupinom odabranom od sljedećih:
Use according to claims 1 to 3, wherein the topical medicament is to be administered in the evening after wash. 
Upotreba u skladu s patentnim zahtjevima 1 do 3, naznačena time što topikalni medikament treba primjenjivati uvečer nakon umivanja.
As the salt concentration decreases, the protein returns to its native conformation and eventually elutes from the column. 
Kako se koncentracija soli smanjuje, protein se vraća u nativnu konformaciju 1 eventualno eluira sa kolone.
Initially H2O content in the sample was 0.18%; during 24 hours at 100% humidity it remains unchanged. 
Početni sadržaj HoO u uzorku bio je 0,18%; nakon 24 sata držanja pri 100%-tnoj vlazi on je ostao nepromijenjen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Plain suction dredging vessel for performing the method according to a preceding claim, the vessel comprising a suction system for pumping sludge from the bottom to the water surface to e.g. a barge moored alongside the vessel, the suction system having an at least one lower suction pipe section for winning sludge at a suction location at the bottom, an anchoring system for anchoring the vessel at a predetermined production location and wherein the anchoring system couples the vessel with the bottom proximate the suction location, 
Plovilo za jednostavno jaružanje usisavanjem, namijenjeno provođenju postupka u skladu s prethodnim patentnim zahtjevom, naznačeno time što plovilo ima: – usisni sustav, namijenjen crpljenju mulja s dna do površine vode, do primjerice teglenice imobilizirane uz plovilo, gdje usisni sustav ima najmanje jedan donji dio usisne cijevi za izvlačenje mulja na mjestu usisavanja na dnu, – sidrišni sustav, namijenjen sidrenju plovila na zadanom mjestu proizvodnje, te gdje sidrišni sustav povezuje plovilo s dnom blizu mjesta usisavanja, gdje sam donji dio usisne cijevi tvori sidrišni sustav i pogodan je za upotrebu kao sidrišna cijev, poput primjerice sidrišnog stupa, gdje najmanje jedan donji dio usisne cijevi sadrži sidrišni dio.
Glatiramer acetate for use according to claim 1 or a medicament comprising glatiramer acetate for use according to claim 2, wherein the frequency and severity of an immediate post injection reaction or an injection site reaction is reduced relative to the daily subcutaneous administration of 20mg glatiramer acetate. 
Glatiramer acetat za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time, da povećava podnošljivost na liječenje glatiramer acetatom kod čovjeka kao pacijenta. Glatiramer acetat za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time, da smanjuje učestalost trenutne reakcije nakon injekcije u odnosu na dnevno supkutano davanje od po 20 mg glatiramer acetata.
The siRNA according to claim 1, which is selected from the following (a) to (s): 
sIRNA koja ima punu dužinu od 21 do 23 nukleotida, naznačena time, da je odabrana od sljedećih (a) do (0):
Method according to claim 1, where the mechanically separated and extracted higher viscosity fraction is treated further. 
- gdje se mehanički odvojenu frakciju više viskoznosti ekstrahira iz postupka;
A method of producing a bonded mineral fiber product which comprises the steps of contacting the mineral fibers with a binder composition according to any one of the claims 1 to 4, and curing the binder composition. 
Postupak proizvodnje proizvoda od vezanih mineralnih vlakana naznačen time da sadrži korake povezivanja mineralnih vlakana uz pomoć vezivnog pripravka prema bilo kojem od zahtjeva 1 do 4, i stvrdnjavanja vezivnog pripravka.
A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
2. < Farmaceutski pripravak naznačen time što sadrži spoj prema zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
The method of any one of 49 to 72, wherein the administering comprises transfecting a cell in the subject with a nucleic acid encoding the alkaline phosphatase. The method of 73, wherein the transfecting the cell is performed in vitro such that the alkaline phosphatase is expressed and secreted in an active form and administered to the subject with said cell. 
Alkalna fosfataza za upotrebu prema bilo kojem zahtjevu od 19 do 21, naznačena time da se uporaba sastoji od transfekcije stanice koja kodira alkalnu fosfatazu u subjekt sa nukleinskom kiselinom, naročito gdje se transfekcija stanice provodi in vitro tako da se alkalna fosfataza eksprimira i izlučuje u aktivnom obliku i daje se subjektu sa navedenom stanicom.
The resin base is typically classified according to the major monomer constituents. 
Baza za smolu je tipično klasificirana prema glavnim monomernim konstituentima.
A compound of formula (XI) or (XIa): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen atom they are linked to form a phthalimido group. 
(Xi) (Xla) naznačen time da R' jest vodik, a R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R* jest trimetilsilil, a R jest tert-butoksikarbonil; ili R 1 R* uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
inducing crystallization of enantiomer (R) and, separately therefrom, inducing crystallization of enantiomer (S); 
poticanje kristalizacije enantiomera (R) i, zasebno, poticanje kristalizacije enantiomera (S);
The salt of claim 8, characterized by spectral d-spacing absorption bands obtained from an X-ray powder diffraction pattern of the same or essentially the same as 3.57,4.80 and 4.99 angstroms. 
Sol prema zahtjevu 8, naznačena time što su d-razmaci spektralnih apsorpcijskih vrpci, koje su dobivene rendgenskom difrakcijom praška, jednaki ili u biti jednaki 3.57,4.80 i 4.99 angstrema.
[Z1] and [L2] are linking moieties which may be the same or different; and [ALBD] is an albumin binding domain of streptococcal protein G, or derivative thereof. 
[L1] i [L2] vezne skupine koje mogu biti jednake ili različite; i [ALBD] je domena za vezanje albumina proteina streptokoka G.
as well as pharmaceutically acceptable salts and polymorphs of said compounds and hydrates of the compounds of formula I and of their salts and mannitol as stabilizer. 
XjeCHiliN, kao i farmaceutski prihvatljive soli i polimorfi navedenih spojeva i hidrata spojeva formule I i njihovih soli i manitol kao stabilizator.
The composition according to claim 10, further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Preparat prema patentnom zahtjevu 10 koji nadalje sadrži najmanje jedan spoj ili polipeptid izabran iz grupe koju čine detektabilna oznaka ili reporter, antagonist TNF, anti-infektivni lijek, lijek za kardiovaskularni (KV) sustav, lijek za središnji živčani sustav (CNS), lijek za autonomni živčani sustav (ANS), lijek za respiratorni trakt, lijek za gastrointestinalni (GI) trakt, hormonski lijek, lijek za održavanje ravnoteže fluida ili elektrolita, hematološki lijek, antineoplastik, imunomodulatorni lijek, oftamološki, otički ili nazalni lijek, topički lijek, nutriticionistički lijek, citokin ili antagonist citokina.
A salt according to claim 7 which also shows on X-ray diffraction peaks on the 2theta scale at 7.0°±0.5°0, 9.2°±0.5°, 11.4°±0.5° and 27.5°±0.5°. A pharmaceutical composition comprising a salt according to claim 1 . A method of treating cancer comprising administration of a therapeutically effective amount of a salt according to claim 1 to a patient in need thereof, 
Sol u skladu s bilo kojim od zahtjeva 1 do 7 koja pod difrakcijom X-zrakama pokazuje pikove na 20 skali na Sol u skladu sa zahtjevom 8 koja pod difrakcijom X-zrakama također pokazuje i najmanje 1 pik na 20 skali izabran iz skupine koja se sastoji od: 10.6%#0.5*, 13%#0.5*, 14.1%+0.5%.
No. 5,968,547 to Reder et al. Transdermal delivery systems of buprenorphine, made by Lohmann Therapie-Systeme GmbH & Co., are currently sold in the European Union under the trademark name TRANSTEC®. 
Sustavi transdermalnog davanja buprenorfina, izrađeni od strane Lohmann Therapie-Systeme GmbH & Co., trenuino se prodaju u Europskoj uniji pod žigom (trgovačkim nazivom) TRANSTECO.
is coupled to the rocker link element and the one or more fulcrum link bars; and/or 
spojena na povezni element podizača i jednu ili više poluga veze s uporištem; i/ili
Sanding element according to claim 1, characterised in that said compressible lamellas (4) contain sanding grains (9). 
Element za brušenje u skladu s patentnim zahtjevom 1, naznačen time, što lamele koje se mogu komprimirati (4) sadržavaju zrnca za brušenje (9).